Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD
Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD
About this item
Full title
Author / Creator
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
Data are reported from SPD503-318, a phase 3, open-label, safety study of guanfacine extended release (GXR) in European children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Participants received dose-optimized GXR (1–7 mg/day) for up to 2 years. Of 215 enrolled participants, 214 were included in the safety population and 1...
Alternative Titles
Full title
Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2002218379
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2002218379
Other Identifiers
ISSN
1018-8827
E-ISSN
1435-165X
DOI
10.1007/s00787-018-1113-4
